We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Holographic Images Show Cellular Response to Anticancer Drug

By Biotechdaily staff writers
Posted on 21 Mar 2007
The response of tumors to anticancer drugs has been observed in real-time three-dimensional (3D) images using shimmer technology. More...
The new digital holographic imaging system uses a laser and a charged couple device (CCD), the same microchip used in household digital cameras, to see inside tumor cells. The device also may have applications in drug development and medical imaging.

"This is the first time holography has been used to study the effects of a drug on living tissue,” said Dr. David D. Nolte, lead investigator and professor of physics from Purdue University (West Lafayette, IN, USA). "We have moved beyond achieving a 3D image to using that image for a direct physiological measure of what the drug is doing inside cancer cells. This provides valuable information about the effects of various doses of the drug and the time it takes each dose to become significantly effective.”

The laser is gentle and does not harm living tissue, according to Dr. Nolte. The cancer cells utilized for the research were grown independently in a bioreactor in the laboratory. Holography uses the full spectrum of information available from light, more than what the human eye can detect, to create a 3D image called a hologram. By shining a laser on both the object and directly on the CCD chip of the digital camera, the system screens the pattern of light reflected from the object and allows the camera to record very detailed data, including depth and motion on a scale of microns, or 0.0001 cm.

The findings of this study were presented on March 6, 2007, at the American Physical Society Meeting, held in Denver, CO, USA. The Purdue researchers detected the motion of organelles inside cancer cells. Organelles are tiny specialized structures that perform internal cell functions and are a common target of anticancer drugs because they play a critical role in the uncontrolled cell division that makes cancer deadly.

Colchicine, the anticancer drug studied by the group, limits the ability of organelles to move throughout the cell and perform their functions. The drug disrupts the growth of microtubules, the highways of the internal cellular structure, and leaves organelles stuck at dead ends unable to move.
This reduction in motion translates to less shimmer in the screen image that can be quantitatively analyzed by a computer program, according to Dr. Nolte.

The investigators now plan to make measurements of the cytoskeleton, the support structure of cells, and to additionally determine what types of motion influence the shimmer effect. "What we have seen is just the tip of the iceberg,” Dr. Nolte said.


Related Links:
Purdue University

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Rapid Sepsis Test
SeptiCyte RAPID
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.